Peter Greenleaf: At least what that would be no, but I think it will — we wouldn’t really find that out, David, in sort of tracking through Aurinia Alliance, why patients might not be picking up their prescription. I think it will bear out more in what we see in terms of the persistency trends over time. I can tell you sort of qualitatively that when we talk to physicians, no one is telling us that they’re looking to use this as an induction and then bridging them to some other therapy. That’s not what the intent of the prescriber is or what we believe they’re doing. And when I say there’s a host of different reasons that patients either discontinue or cancel on a prescription, it is a host. There is no actual one trend of consistency there.
It’s everything from the office didn’t follow through or the patient didn’t follow through. The patient didn’t pick up the prescription, decided not to stay on therapy, couldn’t tolerate the therapy. It is a host of different reasons, including sort of a lost to follow-up. Patients change addresses, they change phone number. So making sure that we’re able to continue to track them down and work very closely as well as we can through our efforts commercially in a compliant way is going to remain to be something that’s top of our list of activities we need to try to drive.
David Martin: Okay. Thanks. And my second question is, do you have any idea of how your lupus nephritis starts and discontinuations compared to Benlysta in lupus nephritis? And any idea what’s driving the decision of physicians to treat with one or the other drug?
Peter Greenleaf: The first part of your answer, and I always hesitate to speak about other drugs, but I will tell you just from what we track, again, through coding and prescribing data is, they see the same sort of challenges. Difference being is they started at a little bit of a higher base. I think if you go back and look at Benlysta utilization, you tag it to ICD-9 codes, they’ve been getting pretty active treatment of lupus nephritis patients long before they had approval for the drug. And I think, again, this is a question for them, but my review of that is that’s as much patients who’ve been on the drug for SLE that stay on it through a patient suffering a lupus nephritis bout and whether the patient — the physician decides to just continue the drug or not is TBD.
Their new patient growth and their adherence, at least from what we can see and discontinuation results are in line with what we’re seeing right now. So I do think its population and not drug based from what I can see. How physicians are making a decision on Benlysta versus our drug is a little bit across the board. But what we do know is that physicians have a unique patient mind for our drug that’s different than Benlysta. And we do know that our messaging around the results we’ve produced in AURORA 1 and in the AURORA 2 continuation study resonate with physicians. I mean, they directly align what the treatment goals are for therapy here. And right now, at least from what we can see, our data best aligns to the guidelines that are out there in terms of treatment outcomes.
So we think we got a good position there, David.
David Martin: Okay. Thanks.
Operator: Thank you. This concludes our question-and-answer session, and thus concludes our call today. We thank you for your interest and participation. You may now disconnect your lines.
